%0 Journal Article
%T Efficacy of delayed pegfilgrastim administration following consolidation therapy with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) patients.
%A Yingling SK
%A Francis J
%A Seago K
%A Safi SUD
%A Wen S
%A Cumpston A
%J Support Care Cancer
%V 32
%N 5
%D 2024 Apr 9
%M 38589646
%F 3.359
%R 10.1007/s00520-024-08480-9
%X <B>OBJECTIVE: </B>To study the effects of delaying pegfilgrastim administration following high-dose cytarabine (HiDAC) consolidation in AML patients on time to neutrophil count recovery, infectious complications, and survival.<BR><B>METHODS: </B>Single-center retrospective chart review of 55 patients receiving pegfilgrastim as early administration (within 72 h) or delayed administration (after 72 h) of HiDAC.<BR><B>RESULTS: </B>The difference in neutrophil recovery time was similar between the early and delayed groups (18 days versus 19 days, p < 0.28). Infections were seen in four patients in the early administration group following chemotherapy compared to none in the delayed group (p = 0.04). Febrile neutropenia rates were also decreased in the delayed administration group (23.1% versus 10.3%, p = 0.28) as well as a trend towards longer median survival (16 months versus 19 months, p = 0.69) and overall survival (21 months versus 31 months, p = 0.47).<BR><B>CONCLUSIONS: </B>A difference in time to neutrophil recovery was not observed between the early and delayed administration groups yet decreased infectious complications may support the delayed administration of pegfilgrastim in these patients.